Clinical Scorecard: Exploring Bladder Preservation Strategies and Systemic Therapy in Localized Muscle-Invasive Bladder Cancer

At a Glance

Key Highlights

• Trimodality therapy (TMT) offers equivalent or potentially superior disease control and overall survival compared to radical cystectomy (RC) in localized MIBC.
• Advances in radiotherapy techniques (3D-CRT, IMRT, VMAT, image-guided radiotherapy) improve targeting and reduce toxicity in bladder preservation.
• Hypofractionated radiotherapy regimens provide superior locoregional control with comparable toxicity and greater patient convenience than conventional fractionation.

Guideline-Based Recommendations

Diagnosis

• Clinical staging of MIBC (cT2-T4N0M0) to determine suitability for bladder preservation or radical cystectomy.

Management

• Offer bladder preservation with trimodality therapy (maximal TURBT, radiotherapy with concurrent radiosensitisers) as an alternative to radical cystectomy.
• Use hypofractionated radiotherapy regimens (e.g., 55 Gy in 20 fractions over 4 weeks) for radical treatment of MIBC.
• Employ advanced radiotherapy techniques (IMRT, VMAT, image-guided radiotherapy) to optimize dose delivery and minimize toxicity.
• Consider patient preference and informed choice when selecting between bladder preservation and radical cystectomy.

Monitoring & Follow-up

• Monitor for treatment-related toxicity, particularly grade 3 or higher adverse events during and after radiotherapy.
• Use daily imaging to assess bladder size, shape, and position to adjust radiotherapy margins and ensure accurate targeting.

Risks

• Radical cystectomy is associated with significant morbidity.
• Potential for occult lymph node metastases despite negative imaging; however, elective pelvic nodal radiotherapy has not shown benefit.
• Radiotherapy toxicity risks mitigated by advanced delivery techniques and hypofractionation.

Patient & Prescribing Data

Patients with localized muscle-invasive bladder cancer eligible for bladder preservation or radical cystectomy.

Bladder preservation with trimodality therapy yields equivalent or improved 5-year overall survival compared to radical cystectomy, with improved convenience and potentially lower morbidity.

Clinical Best Practices

• Present both radical cystectomy and bladder preservation with trimodality therapy as treatment options to patients to support informed decision-making.
• Utilize maximal transurethral resection of bladder tumour (TURBT) prior to radiotherapy to optimize bladder preservation outcomes.
• Adopt hypofractionated radiotherapy regimens to improve locoregional control and patient convenience.
• Incorporate advanced radiotherapy techniques and daily image guidance to reduce treatment margins and toxicity.
• Consider ongoing clinical trial data (e.g., RAIDER trial) for dose escalation strategies and adaptive radiotherapy approaches.

References

• 1. Traditional standard treatment for MIBC
• 3. Evidence supporting equivalence of TMT and RC
• 4. Clinical guidelines endorsing radiosensitisers with radiotherapy
• 5. Long-term survival data for radiotherapy with radiosensitisers
• 6,7. Challenges in RCT comparing RC and bladder preservation
• 8,9. Retrospective analyses showing equivalent outcomes
• 10. Outcomes in clinical node-positive MIBC
• 11. Advances in radiotherapy delivery techniques
• 12. Meta-analysis supporting hypofractionation
• 13. UK radiotherapy dose regimens for MIBC
• 14,15. BC2001 and BCON trials
• 16. RAIDER trial results on adaptive radiotherapy
• 17. Daily imaging for bladder motion management
• 18. Occult lymph node metastases in surgical series
• 19. Incidental radiation dose to lymph nodes
• 20. Lack of benefit from elective pelvic nodal radiotherapy